Pregabalin, a calcium channel α2-δ ligand, modulates neurotransmitter release by binding to voltage-gated calcium channels, potentially reducing cortical hyperexcitability associated with Visual Snow Syndrome. By decreasing glutamatergic neurotransmission and enhancing GABAergic inhibition, it may improve sleep architecture and reduce sensory processing abnormalities, leading to improved sleep quality and reduced visual disturbances.